Translational Cancer Research on Urogenital Malignancies

Prostate Cancer + Bone Xenografts

I think everyone realizes that there’s something “particular” about prostate cancer bone metastases and the mineralized hydroxyapatite that surrounds these metastases. I had the recent pleasure of conversing with Dr. Leland Chung, the person who discovered that RANKL antagonization might be beneficial for these patients. We’ve been working on a prostate cancer bone metastasis model where we mix PC-3M-LN4 cells with modified hydroxyapatite and they form very nice “xenografts”. Next step: adipocytes!